title: Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.
abstract: Ergotamine inhibits the sympathetically-induced tachycardia in pithed rats. The present study identified the pharmacological profile of this response. Male Wistar rats were pithed and prepared to stimulate the preganglionic (C(7)-T(1)) cardiac sympathetic outflow. Intravenous continuous infusions of ergotamine dose-dependently inhibited the tachycardic responses to sympathetic stimulation, but not those to exogenous noradrenaline. Using several antagonists, the sympatho-inhibition to ergotamine was: (1) partially blocked by rauwolscine (alpha(2)), haloperidol (D(1/2)-like) or rauwolscine plus GR127935 (5-HT(1B/1D)); (2) abolished by rauwolscine plus haloperidol; and (3) unaffected by either saline or GR127935. In animals systematically pretreated with haloperidol, this sympatho-inhibition was: (1) unaffected by BRL44408 (alpha(2A)), partially antagonized by MK912 (alpha(2C)); and (3) abolished by BRL44408 plus MK912. These antagonists failed to modify the sympathetically induced tachycardic responses per se. Thus, the cardiac sympatho-inhibition by ergotamine may be mainly mediated by alpha(2A)/alpha(2C)-adrenoceptors, D(2)-like receptors and, to a lesser extent, by 5-HT(1B/1D) receptors.
authors.affiliation: Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de los Tenorios 235, Col. Granjas-Coapa, Deleg. Tlalpan, C.P. 14330, México D.F., México.
authors.forename: Luis E
authors.initials: LE
authors.lastname: Cobos-Puc
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Villalón
authors.forename: Araceli
authors.initials: A
authors.lastname: Sánchez-López
authors.forename: Martha B
authors.initials: MB
authors.lastname: Ramírez-Rosas
authors.forename: Jair
authors.initials: J
authors.lastname: Lozano-Cuenca
authors.forename: Heinz H
authors.initials: HH
authors.lastname: Pertz
authors.forename: Tilo
authors.initials: T
authors.lastname: Görnemann
authors.forename: David
authors.initials: D
authors.lastname: Centurión
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D003655:Decerebrate State; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004878:Ergotamine / Q000008:administration & dosage / Q000494:pharmacology*; D007262:Infusions, Intravenous; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D044302:Receptor, Serotonin, 5-HT1B / Q000502:physiology; D044346:Receptor, Serotonin, 5-HT1D / Q000502:physiology; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013610:Tachycardia / Q000503:physiopathology
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000316:Adrenergic alpha-Agonists; D065127:Dopamine D2 Receptor Antagonists; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D018341:Receptors, Adrenergic, alpha-2; D017448:Receptors, Dopamine D2; D004878:Ergotamine
references.citation: Eur J Clin Pharmacol. 1984;26(4):463-70
references.pmid: 6428916
references.citation: Life Sci. 1999;64(20):1839-47
references.pmid: 10350358
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30
references.pmid: 18066532
references.citation: J Cardiovasc Pharmacol. 1987 Jun;9(6):686-93
references.pmid: 2442535
references.citation: Eur J Pharmacol. 1978 Jul 1;50(1):51-60
references.pmid: 210023
references.citation: J Pharmacol Exp Ther. 1987 Mar;240(3):944-53
references.pmid: 2882016
references.citation: Br J Pharmacol. 1970 Oct;40(2):257-67
references.pmid: 5275866
references.citation: Br J Pharmacol. 2003 Oct;140(4):725-35
references.pmid: 14504136
references.citation: Eur J Clin Pharmacol. 1984;26(6):699-705
references.pmid: 6489409
references.citation: Br J Pharmacol. 1994 Feb;111(2):539-46
references.pmid: 7911719
references.citation: Fundam Clin Pharmacol. 1992;6(2):67-73
references.pmid: 1351472
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20
references.pmid: 9303567
references.citation: J Pharmacol Exp Ther. 2000 Jan;292(1):54-66
references.pmid: 10604931
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24
references.pmid: 9459568
references.citation: Eur J Pharmacol. 1979 Oct 1;58(3):305-12
references.pmid: 510361
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):46-53
references.pmid: 15224175
references.citation: Neuropharmacology. 1995 Feb;34(2):235-7
references.pmid: 7617149
references.citation: Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12
references.pmid: 8380639
references.citation: Arch Int Pharmacodyn Ther. 1986 Nov;284(1):30-7
references.pmid: 2881518
references.citation: J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65
references.pmid: 7996470
references.citation: Biochem Pharmacol. 1998 Apr 1;55(7):1035-43
references.pmid: 9605427
references.citation: Neurosci Biobehav Rev. 2000 Jan;24(1):125-32
references.pmid: 10654668
references.citation: Eur J Pharmacol. 2007 Jan 12;554(2-3):205-11
references.pmid: 17109851
references.citation: Brain. 2000 Jan;123 ( Pt 1):9-18
references.pmid: 10611116
references.citation: J Auton Pharmacol. 1999 Feb;19(1):55-63
references.pmid: 10385270
references.citation: J Auton Pharmacol. 1988 Dec;8(4):297-302
references.pmid: 2855331
references.citation: J Recept Res. 1988;8(1-4):59-81
references.pmid: 3290473
references.citation: Br J Pharmacol. 1994 May;112(1):323-31
references.pmid: 8032658
references.citation: Headache. 2003 Feb;43(2):144-66
references.pmid: 12558771
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):220-7
references.pmid: 14673512
references.citation: J Appl Physiol. 1964 Mar;19:360-2
references.pmid: 14155315
references.citation: Br J Pharmacol. 1996 Sep;119(2):330-4
references.pmid: 8886417
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209
references.pmid: 18347570
references.citation: Gen Pharmacol. 1988;19(3):475-81
references.pmid: 2843416
references.citation: Proc Soc Exp Biol Med. 1947 Apr;64(4):453-5
references.pmid: 20239456
references.citation: Pharmacol Rev. 1994 Jun;46(2):157-203
references.pmid: 7938165